Ionis has shared a letter with the Angelman syndrome community in response to last week’s announcement on the outcome of the ASPIRE GTX-102 Phase 3 clinical trial.
The letter shares information about the obudanersen (ION582) program and addresses some of the questions Ionis has received from the community. Ionis remains committed to continue evaluating the safety and efficacy of obudanersen (ION582) through three clinical trials: HALOS, REVEAL, and CHAMPION.
On October 8, 2026, ASF and FAST hosted a webinar with Ultragenyx after the announcement that their phase 3 trial for GTX-102 (aspire) did not meet primary or key secondary
Read the press release
Read the letter from Ultragenyx to the community: Angelman-Syndrome-Community-Update-9.16
Following the recent announcement on the outcome of the phase 3 Aspire trial of GTX-102, Oak Hill Bio has shared a message about their commitment to evaluate rugonersen in their
Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.
